by blood component transfusion A linked donor-recipient study to evaluate parvovirus B19 transmission

[1]  M. Busch,et al.  Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion , 2009, Transfusion.

[2]  Y. Tani,et al.  Persistent infection by human parvovirus B19 in qualified blood donors , 2008, Transfusion.

[3]  P. Simmonds,et al.  Parvoviruses and blood transfusion , 2007, Transfusion.

[4]  S. Glynn,et al.  Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay , 2007, Transfusion.

[5]  E. Seifried,et al.  Blood donor screening for parvovirus B19 in Germany and Austria , 2007, Transfusion.

[6]  A. Parsyan,et al.  Human erythrovirus B19 and blood transfusion – an update , 2007, Transfusion medicine.

[7]  Y. Geng,et al.  Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing , 2007, Transfusion.

[8]  A. Parsyan,et al.  Effects of transfusion on human erythrovirus B19‐susceptible or ‐infected pediatric recipients in a genotype 3–endemic area , 2006, Transfusion.

[9]  S. Doyle,et al.  The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. , 2006, The Journal of infectious diseases.

[10]  E. Holler,et al.  Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products , 2005, Transfusion.

[11]  J. Lefrère,et al.  Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. , 2005, Blood.

[12]  Nitin R. Patel,et al.  Exact Inference for Categorical Data , 2005 .

[13]  C. Nass,et al.  The RADAR repository: a resource for studies of infectious agents and their transmissibility by transfusion , 2005, Transfusion.

[14]  B. Evatt,et al.  Parvovirus B19 transmission by a high‐purity factor VIII concentrate , 2005, Transfusion.

[15]  A. Parsyan,et al.  Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor Samples , 2004, Journal of Virology.

[16]  S. Doyle,et al.  Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. , 2004, Journal of medical microbiology.

[17]  M. Di Giambattista,et al.  Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non‐structural viral proteins , 2003, Vox sanguinis.

[18]  J. Löwer,et al.  Parvovirus B19 transmission by heat‐treated clotting factor concentrates , 2002, Transfusion.

[19]  W. Hitzler,et al.  Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction , 2002, Vox sanguinis.

[20]  N. Young,et al.  Parvovirus B19: implications for transfusion medicine. Summary of a workshop , 2001, Transfusion.

[21]  T. Eastlund,et al.  Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasma , 2000, Transfusion.

[22]  J. Kiss,et al.  Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients , 1998, Vox Sanguinis.

[23]  M. Ferguson,et al.  Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. , 1997, Biologicals (Print).

[24]  J. Goldman,et al.  Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion , 1997, Transfusion.

[25]  M. Morfini,et al.  Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization , 1997 .

[26]  Y. Yoto,et al.  Incidence of human parvovirus B19 DNA detection in blood donors , 1995, British journal of haematology.

[27]  A. Zanella,et al.  Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patient , 1995, Transfusion.

[28]  N. Young,et al.  Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). , 1994, The New England journal of medicine.

[29]  P. Mannucci,et al.  Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates , 1992, American journal of hematology.

[30]  N. Young.  Hematologic and hematopoietic consequences of B19 parvovirus infection. , 1988, Seminars in hematology.

[31]  P. Mortimer,et al.  TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATES , 1983, The Lancet.